AI Article Synopsis

  • The study examined early-stage ovarian cancer survivors who developed second primary malignancies (SPMs) and created a prediction tool to assess individual risks for these SPMs.
  • Using data from the SEER database and analyzing 14,314 patients, the findings indicated that factors like older age, white race, certain ovarian cancer subtypes, and previous radiotherapy were linked to a higher risk of SPMs.
  • The proposed risk assessment model showed greater clinical benefits compared to generalized screening approaches, suggesting it could help doctors tailor follow-up care for patients based on their risk levels.

Article Abstract

Purpose: This study aimed to characterize the clinical features of early-stage ovarian cancer (OC) survivors with second primary malignancies (SPMs) and provided a prediction tool for individualized risk of developing SPMs.

Methods: Data were obtained from the Surveillance, Epidemiology and End Results (SEER) database during 1998-2013. Considering non-SPM death as a competing event, the Fine and Gray model and the corresponding nomogram were used to identify the risk factors for SPMs and predict the SPM probabilities after the initial OC diagnosis. The decision curve analysis (DCA) was performed to evaluate the clinical utility of our proposed model.

Results: A total of 14,314 qualified patients were enrolled. The diagnosis rate and the cumulative incidence of SPMs were 7.9% and 13.6% [95% confidence interval (CI) = 13.5% to 13.6%], respectively, during the median follow-up of 8.6 years. The multivariable competing risk analysis suggested that older age at initial cancer diagnosis, white race, epithelial histologic subtypes of OC (serous, endometrioid, mucinous, and Brenner tumor), number of lymph nodes examined (<12), and radiotherapy were significantly associated with an elevated SPM risk. The DCA revealed that the net benefit obtained by our proposed model was higher than the all-screening or no-screening scenarios within a wide range of risk thresholds (1% to 23%).

Conclusion: The competing risk nomogram can be potentially helpful for assisting physicians in identifying patients with different risks of SPMs and scheduling risk-adapted clinical management. More comprehensive data on treatment regimens and patient characteristics may help improve the predictability of the risk model for SPMs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161780PMC
http://dx.doi.org/10.3389/fonc.2022.875489DOI Listing

Publication Analysis

Top Keywords

second primary
8
primary malignancies
8
early-stage ovarian
8
ovarian cancer
8
cancer survivors
8
risk prediction
4
prediction second
4
malignancies primary
4
primary early-stage
4
survivors seer-based
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!